期刊文献+

早期乳腺癌保留乳房手术后全乳腺大分割放射治疗与常规分割放射治疗的随机对照研究 被引量:8

Comparison between short-course whole breast hypofractionated radiotherapy and conventional fractionated radiotherapy after breast-conserving surgery for early stage breast cancer patients: a randomized controlled study
原文传递
导出
摘要 目的比较早期乳腺癌患者保留乳房(简称保乳)手术后行全乳大分割并瘤床同步加量24 d短疗程放射治疗(简称放疗)与44 d常规分割方案的近期疗效、不良反应和美容效果。方法选择2011年1月至2011年12月天津医科大学肿瘤医院收治的保乳术后病理分期为p T1~2N0~1M0的早期乳腺癌患者共80例,应用随机数字表法将患者分为短疗程放疗组(40例)和常规放疗组(40例)。短疗程放疗组(简称短程组)患者行全乳两野切线放射治疗,单次剂量为2.4 Gy,共18次,总剂量为43.2 Gy,同步行瘤床电子线推量照射,单次剂量为0.4 Gy,共18次,瘤床总剂量为50.4 Gy,总疗程24 d;常规放疗组(简称常规组)患者行全乳两野切线放射治疗,单次剂量为1.8 Gy,共25次,总剂量为45.0 Gy,后续行瘤床电子线推量照射,单次剂量为2.0 Gy,共7次,瘤床总剂量为59.0 Gy,总疗程44 d。采用KaplanMeier法计算患者的局部复发率和生存率,用Log-rank检验比较两组间的差异,并用χ2检验比较两组间不良反应及美容效果的差异。结果中位随访时间37个月,随访率为100%。两组患者的3年生存率均为100%(χ2〈0.001,P=1.000),且均无一例局部复发。短程组与常规组相比,0~1级、2级急性皮肤不良反应发生率均相似[82.5%(33/40)比77.5%(31/40),χ2=0.313,P=0.576;17.5%(7/40)比22.5%(9/40),χ2=0.313,P=0.576];1级皮肤及皮下组织晚期不良反应发生率也相似[22.5%(9/40)与20.0%(8/40),χ2=0.075,P=0.785];美容效果优良率也相近[67.5%(27/40)与72.5%(29/40),χ2=0.238,P=0.626]。放疗引起的血液学毒性主要表现为1~2级的中性粒细胞减少和1级血小板下降,并且短程组与常规组的发生率接近[12.5%(5/40)比10.0%(4/40),χ2=0.125,P=0.724;2.5%(1/40)比5.0%(2/40),P=1.000]。结论早期乳腺癌患者保乳术后行全乳大分割并瘤床同步加量放疗可以缩短术后放疗疗程,近期疗效好,且不影响美容效果,也不加重皮肤不良反应,但远期效果还需进行长期随访,进一步研究。 Objective To compare the short-term efficacy,adverse reaction and cosmetic outcome between whole breast irradiation of short-course( 24 d) hypofractionated radiotherapy with concomitant tumor bed boost and conventional regimen( 44 d) after breast-conserving surgery for early stage breast cancer patients.Methods A total of 80 patients with p T1-2N0-1M0 breast cancer treated by breast-conserving surgery in Cancer Institute and Hospital,Tianjin Medical University from January 2011 to December 2011 were divided into shortcourse radiotherapy group( n = 40) and conventional radiotherapy group( n = 40) using a random number table method.In short-course radiotherapy group,40 patients received whole breast radiation of 43. 2 Gy( 2. 4 Gy each fraction,18 fractions) with concomitant tumor bed boost of 7. 2 Gy( 0. 4 Gy each fraction,18 fractions)( total dose: 50. 4 Gy,duration: 24 d). In conventional radiotherapy group,40 patients received whole-breast radiation of 45. 0 Gy( 1. 8 Gy each fraction,25 fractions) followed by tumor bed boost of 14. 0 Gy( 2. 0 Gy each fraction,7 fractions)( total dose: 59. 0 Gy,duration: 44 d). Kaplan-Meier method was used to calculate the local recurrence and overall survival,and the differences between two groups were analyzed by Log-rank test.χ2test was used to compare the differences in adverse reaction and cosmetic outcome between the two groups. Results All patients were followed up for median 37 months,and the follow-up rate was 100%. The 3-year overall survival rates in two groups were both 100%( χ2〈 0. 001,P = 1. 000). No patient developed local recurrence.The incidence of grade 0- 1 acute adverse reaction of skin was 82. 5%( 33 / 40) in short-course radiotherapy group and 77. 5%( 31 / 40) in conventional radiotherapy group( χ2= 0. 313,P = 0. 576),and the incidence of grade 2 adverse reaction was 17. 5%( 7 / 40) in short-course radiotherapy group and 22. 5%( 9 / 40)in conventional radiotherapy group( χ2= 0. 313,P = 0. 576). The adverse reaction of skin and subcutaneous tissue in grade l developed in 22. 5%( 9 / 40) of short-course radiotherapy group and 20%( 8 / 40) of conventional radiotherapy group( χ2= 0. 075,P = 0. 785). Totally 67. 5%( 27 / 40) of patients in short-course radiotherapy group and 72. 5%( 29 / 40) of patients in conventional radiotherapy group had good cosmetic outcome( χ2= 0. 238,P = 0. 626). The radiotherapy-induced blood toxicity was mainly manifested as grade 1 to2 neutropenia and grade 1 thrombocytopenia,the former occurred in 12. 5%( 5 / 40) of patients in short-course radiotherapy group and 10%( 4 / 40) of conventional radiotherapy group( χ2= 0. 125,P = 0. 724),and the latter occurred in 2. 5%( 1 / 40) of short-course radiotherapy group and 5%( 2 / 40) of conventional radiotherapy group( P= 1. 000). Conclusion Short-course whole breast hypofractionated radiotherapy with concomitant tumor bed boost can shorten the duration of postoperative radiotherapy,and obtain good short-term effect without affecting cosmetic effect or increasing the skin adverse reactions,however,long-term effects need to be confirmed by long-term follow-up and further study.
出处 《中华乳腺病杂志(电子版)》 CAS CSCD 2015年第3期163-167,共5页 Chinese Journal of Breast Disease(Electronic Edition)
关键词 乳腺肿瘤 外科学 放射疗法 放射治疗剂量 治疗结果 Breast neoplasms Surgery Radiotherapy Radiotherapy dosage Treatment outcome
  • 相关文献

参考文献17

  • 1Keating NL, Landrum MB, Brooks JM, et al. Outcomesfollowing local therapy for early-stage breast cancer in non-trialpopulations[ J ] . Breast Cancer Res Treat, 2011,125 ( 3 ):803-813.
  • 2Bartelink H, Horiot JC, Poortmans PM, et al. Impact of ahigher radiation dose on local control and survival in breast-conserving therapy of early breast cancer : 10-year results of therandomized boost versus no boost EORTC 22881-10882 trial[J]. J Clin Oncol, 2007,25(22) : 3259-3265.
  • 3Tortorelli G, Di Murro L, Barbarino R, et al. Standard orhypofractionated radiotherapy in the postoperative treatment ofbreast cancer: a retrospective analysis of acute skin toxicity anddose inhomogeneities[ J] . BMC Cancer, 2013 ,13 :230.
  • 4Abner AL, Recht A, Vicini FA, et al. Cosmetic results aftersurgery, chemotherapy, and radiation therapy for early breastcancer [ J]. Int J Radial Oncol Biol Phys, 1991, 21 ( 2 );331-338.
  • 5姜军.乳腺癌的精准诊疗:临床发展新趋势[J].中华乳腺病杂志(电子版),2014,8(2):1-3. 被引量:19
  • 6孙春雷,周士福,孟东,时伟锋,赵于天,金建荣,吕庆,陈玲,杭建萍,李励琦.具备保留乳房条件的早期乳腺癌治疗方式选择[J].中华乳腺病杂志(电子版),2013,7(1):31-34. 被引量:6
  • 7Whelan T, MacKenzie R, Julian J, et al. Randomized trial ofbreast irradiation schedules after lumpectomy for women withlymph node-negative breast cancer [ J ]. J Natl Cancer Inst,2002,94(15) : 1143-1150.
  • 8Whelan TJ, Pignol JP, Levine MN,et al. Long-term results ofhypofractionated radiation therapy for breast cancer m. nEngl J Med, 2010,362(6) : 513-520.
  • 9Herbert C, Nichol A, Olivotto I, et al. The impact ofhypofractionated whole breast radiotherapy on local relapse inpatients with Grade 3 early breast cancer : a population-basedcohort study [J]. Int J Radiat Oncol Biol Phys, 2012,82(5):2086-2092.
  • 10START Trialists’ Group, Bentzen SM, Agrawal RK,et al. TheUK Standardisation of Breast Radiotherapy ( START) Trial A ofradiotherapy hypofractionation for treatment of early breastcancer: a randomised trial [ J]. Lancet Oncol, 2008,9(4):331-341.

二级参考文献40

  • 1张保宁,邵志敏,乔新民,李波,姜军,杨名添,王水,宋三泰,张斌,杨红健.中国乳腺癌保乳治疗的前瞻性多中心研究[J].中华肿瘤杂志,2005,27(11):680-684. 被引量:247
  • 2Keating NL, Landrum MB, Brooks JM, et al. Outcomes followinglocal therapy for early-stage breast cancer in non-trial populations. Breast Cancer Res Treat,2011,125:803-813.
  • 3Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med, 2001,345: 1378- 1387.
  • 4Hall EJ. Time, dose and fractionation in radiotherapy//Hall EJ. Radiobiology for the radiologist. Philadelphia : Lippincott Williams & Willkins ,2000 :409-415.
  • 5Blockhuys S, Vanhoecke B, Paelinck L, et al. Development of in vitro models for investigating spatially fractionated irradiation: physics and biological results. Phys Med Biol, 2009,54: 1565- 1578.
  • 6余子豪,王淑莲,吴君心,等.早期乳腺癌根治术后辅助放射治疗的研究//孙燕,马军.中国临床肿瘤学教育专辑(2006).北京:中国协和医科大学出版社,2006:384-388.
  • 7Whelan T, MacKen Z, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node negative breast cancer. J Natl Caner Inst,2002,94 : 1143-1150.
  • 8Whelan TJ , Pignol JP , Levine MN , et al. Long - term results ofhypofractionated radiation therapy for breast cancer. N Engl J Med,2010,362:513-520.
  • 9Sartor CI, Tepper JE. ls less more? Lessons in radiation schedules in breast cancer. J Natl Caner Ints ,2002,94 : 1114-1115.
  • 10Hopwood P, Haviland JS, Sumo G, et al. The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol,2008,9:331-341.

共引文献58

同被引文献62

引证文献8

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部